Emicizumab

6 trials 3 recruiting BHaematology

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

3 Recruiting

3 Completed trials

4 Sponsors

14 Countries

Phase III

Phase III/IV

Phase IV

Phase III: 3 Phase III/IV: 1 Phase IV: 2

Indications tested

Von Willebrand´s disease 1

Sponsors using this IMP

F. Hoffmann-La Roche AG 4 Emory University 1 HZRM Haemophilie-Zentrum Rhein Main GmbH 1 Universitair Medisch Centrum Utrecht 1

All trials

6 total

A Study to assess safety and effectiveness of Emicizumab in Patients with Type 3 Von Willebrand Disease Recruiting

2024-515622-80-00 Phase III 8 countries F. Hoffmann-La Roche AG
Pharmacokinetic-guided dosing of emicizumab in congenital haemophilia A patients – The DosEmi study Recruiting

2024-515528-35-00 Phase III/IV 1 country Universitair Medisch Centrum Utrecht
An international investigator initiated trial to capture different approaches in the treatment of Haemophilia A Patients With FVIII Inhibito… Recruiting

2024-516741-39-00 Phase IV 7 countries Emory University; HZRM Haemophilie-Zentrum Rhein Main GmbH
A Study to Evaluate Overall Health, Physical Activity and Joint Outcomes, in Participants with Severe or Moderate Hemophilia A without FVIII… Ended

2023-505747-40-00 Phase IV 4 countries F. Hoffmann-La Roche AG
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12… Ended

2023-505964-13-00 Phase III 6 countries F. Hoffmann-La Roche AG
A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of emicizumab in patients with mild or moderate hemophilia A… Ended

2023-506610-52-00 Phase III 3 countries F. Hoffmann-La Roche AG

Showing 1–6 of 6 trials

← All drugs A–Z